This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://www.rxlist.com/cgi/generic3/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00065/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00065/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00065/identifier/drugbank/
n18http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/patent/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00065/identifier/uniprotkb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00065/identifier/genbank/
n23http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00065
rdf:type
n3:Drug
n3:description
Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion
n3:dosage
n9:271B42F4-363D-11E5-9242-09173F13E4C5 n9:271B42F5-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993 Nov;30(16):1443-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8232330 #American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Infliximab; [updated 2014 Aug 27; cited 2014 Nov 12]. Available fromhttp://web.b.ebscohost.com/dynamed/detail?vid=15&sid=c9ea9657-342a-4b9b-a3bb-bf363d5d58c4%40sessionmgr112&hid=110&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232803&anchor=Mechanism-of-Action-Pharmacokinetics # Dubinsky MC, Fleshner PP: Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes. Curr Treat Options Gastroenterol. 2003 Jun;6(3):183-200. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12744819 # Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398-405. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10228190 # Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 Feb 26;350(9):876-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14985485 # Hanauer SB: Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb;17(1):131-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12617888 # http://www.google.co.in/patents/US8524217 #Lexicomp Online (2014). Infliximab Available at: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7084#f_pharmacology-and-pharmacokinetics [Accessed 12 Nov. 2014].
n3:group
approved
n3:halfLife
9.5 days (7-12 days) in patients with Crohn's disease, plaque psoriasis and rheumatoid arthritis
n3:indication
To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis.
n3:manufacturer
n24:271B42F1-363D-11E5-9242-09173F13E4C5
owl:sameAs
n18:DB00065 n26:DB00065
dcterms:title
Infliximab
adms:identifier
n11:DB00065 n14:PA452639 n15:P01857 n16:J00228 n20:Infliximab
n3:mechanismOfAction
Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa. TNFa activation normally induces the release of proinflammatory cytokines, the enhancement of leukocyte migration and activation of neutrophils among others. Neutralization of the biological activity of TNFa leads to an overall reduction in inflammation.
n3:packager
n24:271B42EF-363D-11E5-9242-09173F13E4C5 n24:271B42F0-363D-11E5-9242-09173F13E4C5
n3:patent
n19:2106299
n3:synonym
Ig gamma-1 chain C region
n3:volumeOfDistribution
3-6 L
n21:hasAHFSCode
n22:92-00-00
n12:hasConcept
n13:M0282056
foaf:page
n6:infliximab.html n7:infliximab.htm
n3:Molecular-Formula
n4:271B42FA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B42F9-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n23:L04AB02
n3:absorption
Onset of action occurs in about 2 weeks in Crohn's disease.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
170277-31-3
n3:category
n3:containedIn
n8:271B42F2-363D-11E5-9242-09173F13E4C5 n8:271B42F3-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n4:271B42F7-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n4:271B42F8-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B42F6-363D-11E5-9242-09173F13E4C5